Induction of natural killer cell activity and perforin and granzyme B gene expression following continuous culture or short pulse with interleukin-12 in young and old mice

European Cytokine Network

Volumn 11, Issue 1, 2000, Pages 59-65

  Argentati, Katy ^a   Bartozzi, Beatrice ^a   Bernardini, Giovanni ^a   Di Stasio, Grazia ^a   Provinciali, Mauro ^a  

^a INRCA   (Italy)

Author keywords

Aging; Granzyme; IL 12 pulse; Mice; NK cell activity; Perforin

Indexed keywords

GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 2; PERFORIN;

AGE; ANIMAL CELL; ARTICLE; CELL CULTURE; GENE EXPRESSION; MALE; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; SPLEEN LYMPHOCYTE;

AGING; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; SPLEEN; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0034060402     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. 1. Chougnet C, Shearer G M. 1996. Potential clinical applications of interleukin-12. (Review) Curr. Opin. Hematol. 3: 216.
2. 2. Trinchieri G. 1998. Immunobiology of interleukin-12. (Review) Immunol. Res. 17: 269.
3. 3. Gately M K, Desai B B, Wolitzki A G, Quinn P M, Dwyer C M, Podlasky F J, Familletti P C, Sinigaglia F, Chizzonite R, Gubler U, Stern A S. 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147: 874.
4. 4. Gately M K, Wolitzky A G, Quinn P M, Chizzonite R. 1992. Regulation of human cytolytic lymphocyte responses by IL-12. Cell. Immunol. 143: 127.
5. + T lymphocytes. J. Immunol. 151: 2444.
6. 6. DeBlaker-Hohe D F, Yamauchi A, Yu C R, Horvath-Arcidiacono J A, Bloom E T. 1995. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell. Immunol. 165: 33.
7. 7. Lamont A G, Adorini L. 1996. IL-12: a key cytokine in immune regulation. (Review) Immunol. Today 17: 214.
8. 8. Leonard J P, Sherman M L, Fisher G L, Buchanan L J, Larsen G, Atkins M B, Sosman J A, Dutcher J P, Vogelzang N J, Ryan J L. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541.
9. 9. Atkins M B, Robertson M J, Gordon M, Lotze M T, DeCoste M, DuBois J S, Ritz J, Sandler A B, Edington H D, Garzone P D, Mier J W, Canning C M, Battiato L, Tahara H, Sherman M L. 1997. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409.
10. 10. Motzer R J, Rakhit A, Schwartz L H, Olencki T, Malone T M, Sandstrom K, Nadeau R, Parmar H, Bukowski R. 1998. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. 4: 1183.
11. 11. Robertson M J, Cameron C, Atkins M B, Gordon M S, Lotze M T, Sherman M L, Ritz J. 1999. Immunological effects of interleukin-12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 5: 9.
12. 12. Owen-Schuab L B, Loudon W G, Yagita M, Grimm E A. 1988. Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin-2 receptors. Cell. Immunol. 111: 235.
13. 13. Horton S A, Oldham R K, Yannelli J R. 1990. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res. 50: 1686.
14. 14. Palmer P A, Scharenberg J G, Von Blomberg B M, Stam A G, Meijer C J, Roest G J, Franks C R, Scheper R J. 1994. Persistent augmentation of natural-killer and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose. Cancer Immunol. Immunother. 39: 34.
15. 15. Provinciali M, Di Stefano G, Stronati S, Fabris N. 1998. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients. Cytokine 10: 132.
16. 16. Kutza J, Murasko D M. 1996. Age-associated decline in IL-2 and IL-12 induction of LAK cell activity of human PBMC samples. Mech. Ageing Dev. 90: 209.
17. 17. Bloom E T, Thompson W C, Horvath-Arcidiacono J A, Burd P R. 1995. Differential effects of interleukin-12 treatment on gene expression by allostimulated T cells from young and aged mice. Mech. Ageing Dev. 85: 109.
18. + CTL activity among elderly persons and the enhancing effect of IL-12. Mech. Ageing Dev. 94: 25.
19. 19. Provinciali M, Di Stefano G, Fabris N. 1992. Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional Cr51-release assay. J. Immunol. Methods 155: 19.
20. 20. Bryant J, Day R, Whiteside T, Herberman R B. 1992. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J. Immunol. Methods 146: 91.
21. 21. Balducci L, Mowrey K, Parker M. 1992. Pharmacology of antineoplastic agents in older patients. In : Balducci L, Lyman G H, Ershler W B. Eds. Geriatric Oncology, Philadelphia, Lippincott Company: 169.
22. 22. Provinciali M, Di Stefano G, Fabris N. 1995. Evaluation of lymphokine-activated killer cell development in young and old health humans. Nat. Immun. 14: 134.
23. 23. Hendrzak J A, Brunda M J. 1995. Interleukin-12. Biologic activity, therapeutic utility, and role in disease. (Review) Lab. Invest. 72: 619.
24. 24. Henkart PA. 1994. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. (Review) Immunity. 1: 343.
25. 25. Aste-Amezaga M, D'Andre A, Kubin M, Trinchieri G. 1994. Cooperation of natural killer stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell. Immunol. 156: 480.
26. 26. BuerJ, Hilse R, Dalimann I, Grosse J, Kirchner H, Zorn U, Lopez Hanninen E, Franzke A, Duensing S, Poliwoda H, Atzpodien J. 1995. Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimunity by adoptive transfer of short activated killer (SHAK) cells. Cytokines Mol Ther. 1: 39.
27. 27. Wigginton J M, Komschlies K L, Back T C, Franco J L, Brunda M J, Wiltrout R H. 1996. Administration of interleukin-12 with pulse interleukin-2 and rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 88: 38.